Medical Policy Manual

**Topic:** Multimarker and Proteomics-based Serum Testing Related to Ovarian Cancer

**Date of Origin:** November 2012

**Section:** Laboratory

**Last Reviewed Date:** December 2016

**Policy No:** 60

**Effective Date:** February 1, 2017

**IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

**DESCRIPTION**

Multimarker serum tests have been proposed as a method for identifying patients likely to have malignant or benign adnexal masses, prior to surgery.

**Background**

Adult women presenting with an adnexal mass have an estimated 68% likelihood of having a benign lesion.[1] About 6% have borderline tumors, 22% have invasive lesions, and 3% have metastatic disease. The mortality rate, for patients with malignant disease depends on three variables: 1) characteristics of the patient; 2) the biology of the tumor (grade, stage, and type); and 3) the quality of treatment (nature of staging, surgery and chemotherapy used).[2] In particular, comprehensive staging and completeness of tumor resection appear to have a positive impact on patient outcome.

A number of studies have evaluated the role of a variety of practice-related factors that may improve health outcomes in patients with ovarian cancer, including specialty treatment by gynecological oncologists.[3-6] Studies have suggested that this specialty treatment may result in improved outcomes, particularly in patients with advanced stage disease.

Serum-based tests have been proposed to triage patients with malignant versus benign adnexal masses.
A suggested use of the tests is to identify women who have a higher likelihood of malignant disease and may benefit from referral to a gynecologic-oncology specialist. These tests are combinations of several separate lab tests known as multi-analyte assays with algorithmic analyses (MAAA) and are performed on a blood sample by a reference laboratory using a proprietary algorithm.

The OVA1® test algorithm uses five serum biomarkers, CA-125, prealbumin, apolipoprotein A-1, beta 2 microglobulin, and transferrin. A second-generation test called Overa™ replaces prealbumin and beta 2 microglobulin with human epididymis secretory protein 4 and follicle stimulating hormone.

The Risk of Ovarian Malignancy Algorithm (ROMA™) test combines 2 biomarkers, human epididymis secretory protein 4 (HE4) and CA-125, along with menopausal status.

**Regulatory Status**

NOTE: On December 10, 2011, the FDA published an amendment to the regulation for classifying ovarian adnexal mass assessment score test systems to restrict these devices so that a prescribed warning statement that addresses off-label risks be highlighted by a black box warning. The warning is intended to mitigate the risk to health associated with off-label use as a screening test, stand-alone diagnostic test, or as a test to determine whether or not to proceed with surgery.

**The Overa™ test**

In March 2016, the Overa™ test was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process, where it was submitted as the OVA1 Next Generation test. This test was predicated on the OVA1® test, to which the Overa™ test is was considered substantially equivalent.

The intended use carried a boxed warning: “PRECAUTION: The OVA1 Next Generation test should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Next Generation test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.”

**The OVA1® test**

On July 16, 2009, the OVA1® test (Vermillion, Inc. Fremont, CA) was cleared for market by the FDA as a 510(k) submission. No predicate was identified, and the review decision was based on the de novo 510(k) review process which allows novel products with moderate or low-risk profiles and without predicates which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

The intended use carried a boxed warning: “PRECAUTION: The OVA1® test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1® test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.”

**The ROMA™ test**

On September 1, 2011, the Risk of Ovarian Malignancy Algorithm (ROMA™ test, Fujirebio Diagnostics, Inc.) was cleared by the FDA as a 510(k) submission. Because the OVA1 test had been
found to be a class II medical device by virtue of the July 2009 clearance, ROMA was found to be substantially equivalent to that predicate device.

The intended use carried a boxed warning: “PRECAUTION: The ROMA (HE4 EIA+ARCHITECT CA125 II) should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the ROMA (HE4 EIA+ARCHITECT CA125 II) carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.”

MEDICAL POLICY CRITERIA

The Overa™, OVA1®, and ROMA™ tests are considered investigational for all indications, including but not limited to:

1. Preoperative evaluation of adnexal masses to triage for malignancy
2. Screening for ovarian cancer
3. Selecting patients for surgery for an adnexal mass
4. Evaluation of patients with clinical or radiologic evidence of malignancy
5. Evaluation of patients with nonspecific signs or symptoms suggesting possible malignancy
6. Postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment

SCIENTIFIC EVIDENCE

Assessment of a diagnostic technology typically focuses on 3 parameters: 1) technical performance; 2) diagnostic performance (sensitivity, specificity, and positive [PPV] and negative predictive value [NPV]) in appropriate populations of patients; and 3) demonstration that the diagnostic information can be used to improve patient outcomes (clinical utility).

Technical performance of a device is typically assessed with 2 types of studies, those that compare test measurements with a gold standard and those that compare results taken with the same device on different occasions (test-retest). Demonstration of technical performance should include an assessment of its reproducibility and precision.

Diagnostic performance is evaluated by the ability of a test to accurately diagnose a clinical condition in comparison with the gold standard. The sensitivity of a test is the ability to detect a disease when the condition is present (true-positive), while specificity indicates the ability to detect patients who are suspected of disease but who do not have the condition (true-negative). Evaluation of diagnostic performance, therefore, requires independent assessment by the 2 methods in a population of patients who are suspected of disease but who do not all have the disease.
Evidence related to improvement of clinical outcomes with use of this testing assesses the data linking use of a test to changes in health outcomes (clinical utility). While in some cases, tests can be evaluated adequately using technical and diagnostic performance, when a test identifies a new or different group of patients with a disease; randomized trials are needed to demonstrate impact of the test on the net health outcome.

**Technical Performance**

Evidence on the technical performance of these tests was evaluated by the U.S. Food and Drug Administration (FDA) and is available through the FDA website. The final analysis indicated acceptable technical performance of Overa™, OVA1®, and ROMA™ for use in clinical care.\(^8\)\(^{-10}\)

Analytical performance for the OVA1® test demonstrated good test precision (coefficient of variation (CV) ranging from 1% to 7.4%, depending on the sample levels studied) and good reproducibility (CV from 2.8% to 8.9%). The test appears linear, reagent and samples stable, and there was no observed interference evaluating common endogenous substances (hemoglobin, bilirubin, etc.). The second-generation Overa™ test, had an improved analytical performance, with an overall precision CV of 1.54% across all days and sample pools, in contrast to the OVA1®’s overall precision CV of 4.09%. The reproducibility of Overa™ was also slightly improved over the OVA1®, and it demonstrated a similar lack of interference from common endogenous substances.

Analytical performance for the ROMA also exhibited good precision with a total CV ranging from 0.49% to 7.72%, depending on both sample values and menopausal status. The reproducibility of the test was acceptable, with a CV that ranged from 0.98 to 25.9%, with highest values observed in patients with low scores, as expected. The reagents are variably stable, and users are instructed to follow package inserts for stability on each analyte used. The test was unaffected by interference with hemoglobin, bilirubin, lipids, or human anti-mouse antibodies (HAMA). However, high levels of rheumatoid factor (more than 500 IU/mL) did appear to cause elevations in test values, and testing in patients with elevated rheumatoid factor is not recommended.

**Diagnostic Performance**

**Systematic Reviews**

A BlueCross BlueShield Association Technology Evaluation Center (TEC) Assessment was completed in 2012 on “Multi-analyte testing for the evaluation of adnexal masses.”\(^{11}\) The Assessment included evaluation of both the OVA1® and ROMA tests and their impact on health outcomes. The single existing study assessing OVA1® was selected. Studies were selected showing the diagnostic characteristics of ROMA using prespecified cutoff values that assessed diagnostic performance for all types of malignancy, and that did not include healthy subjects as non-malignant control subjects. The TEC Assessment concluded that OVA1® appears to improve sensitivity for detection of malignancy, however specificity declines so much that most patients test positive, and that ROMA does not appear to improve the sensitivity of testing to a great extent.

In 2014, Wang et al. published a meta-analysis of studies evaluating the diagnostic accuracy of the ROMA algorithm and comparing it to the performance of single markers HE4 and CA125.\(^{12}\) To be included in the meta-analysis, studies had to investigate both HE4 and CA125 or calculate ROMA, include women with ovarian cancer and benign gynecologic disease, use pathology diagnosis as the reference standard, and collect blood samples before treatment was initiated. A total of 32 studies met
these inclusion criteria; 6 of these were conducted in the United States. Findings of the overall pooled analysis of diagnostic accuracy are presented in Table 2. Findings were similar when diagnostic performance in premenopausal women and postmenopausal women were evaluated separately. ROMA had similar or higher sensitivity than HE4 and CA125, and HE4 had the highest specificity.

Table 2. Diagnostic Performance of ROMA compared with HE4 and CA125 from Wang et al.: Meta-analysis findings

<table>
<thead>
<tr>
<th></th>
<th>No. Studies</th>
<th>Sensitivity % (95% CI)</th>
<th>Specificity %, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROMA</td>
<td>14</td>
<td>85.3 (81.2-88.6)</td>
<td>82.4 (77.4-86.5)</td>
</tr>
<tr>
<td>HE4</td>
<td>28</td>
<td>76.3 (72.0-80.1)</td>
<td>93.6 (90.0-95.9)</td>
</tr>
<tr>
<td>CA125</td>
<td>28</td>
<td>79.2 (74.0-83.6)</td>
<td>82.1 (76.6-86.5)</td>
</tr>
</tbody>
</table>

In 2016, Dayyani et al conducted a meta-analysis comparing ROMA with HE4 and CA125 in patients with suspected ovarian cancer.[13] Six studies met the inclusion criteria, four of which were included in the 2014 Wang et al meta-analysis. Two studies were published in 2014 or later. Based on area under the curve (AUC) ROMA had higher values than either HE4 or CA125 alone (0.921 [95% CI 0.855 to 0.960] vs 0.899 [95% CI 0.835 to 0.943] and 0.883 [95% CI 0.771 to 0.950] for HE4 and CA125, respectively). Findings of the pooled analysis of diagnostic accuracy are shown in Table 3.

Table 3. Diagnostic Performance of ROMA compared with HE4 and CA125 from Dayyani et al.: Meta-analysis findings

<table>
<thead>
<tr>
<th></th>
<th>No. Studies</th>
<th>Sensitivity % (95% CI)</th>
<th>Specificity %, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROMA</td>
<td>6</td>
<td>87.3 (75.2-94.0)</td>
<td>85.5 (71.9-93.2)</td>
</tr>
<tr>
<td>HE4</td>
<td>6</td>
<td>68.2 (69.3-90.1)</td>
<td>85.1 (71.6-92.8)</td>
</tr>
<tr>
<td>CA125</td>
<td>6</td>
<td>79.6 (66.3-88.5)</td>
<td>82.5 (66.2-91.9)</td>
</tr>
</tbody>
</table>

Clinical Studies

**OVA1®**

Diagnostic performance of the OVA1® test was evaluated in a prospective, double-blind clinical study using 27 demographically mixed subject enrollment sites.[8] Patients underwent a complete clinical evaluation prior to surgical intervention, and only patients with planned surgical intervention were included in the study. The pre-surgical process for identifying patients for surgery and for establishing a preliminary diagnosis as benign or malignant were not specifically described but were noted to be “based on a variety of clinical assessments.” The study did require at least one imaging test be performed within 12 weeks of surgery. Presumably, use of this somewhat non-standardized diagnostic methodology provides information on how the test works in conjunction with real-world decision making. The study enrolled a total of 743 patients with 146 subjects used in the training set and 516 in the testing set. Seventy-four patients were excluded because of missing information or samples. All patients had adnexal masses and were scheduled for surgery. The final prevalence of cancer in the population was 27%.
Using pathologic diagnosis as the gold standard, test performance, when combined with presurgical assessment for benign disease, was as follows in the hands of non-gynecological oncologists:

<table>
<thead>
<tr>
<th></th>
<th>Clinical assessment alone</th>
<th>Clinical assessment with OVA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>72%*</td>
<td>92%</td>
</tr>
<tr>
<td>Specificity</td>
<td>83%</td>
<td>42%</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>61%</td>
<td>37%</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>89%</td>
<td>93%</td>
</tr>
</tbody>
</table>

* Confidence intervals not provided.

OVA1® appeared to improve sensitivity for detection of malignancy; however specificity declined so much that most patients tested positive.

In 2013, Bristow and colleagues reported on a prospective non-randomized study of 494 patients evaluated for multivariate index assay (OVA1®), CA125-II, and clinical impression.[14] Patients were all scheduled to undergo surgery for an adnexal mass and all were recruited from non-gynecological oncology practices. Authors sought to assess the OVA1 test in determining the need for gynecological oncology referral by comparing OVA1® to clinical assessment and CA 125-II in identifying women with ovarian cancer. Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratios were calculated to estimate the performance of OVA1®, CA125, clinical impression, and OVA1 with clinical impression. For ovarian malignancies, authors reported a sensitivity of 95.7% when combined with clinical impression. The negative predictive value was reported at 98.1%. However, both clinical impression and CA125-II were more accurate in identifying benign disease. Similar to the previous study, although sensitivity improved with the OVA1® test, specificity declined and was reported as 53.5% with OVA1® alone and 50.7% with OVA1® combined with clinical impression compared to 92.5% with clinical impression and 86.1% -94.5% for CA125-II in predicting disease.

Further analysis of combined data from the 2013 Bristow et al. study[14] and another published OVA1® study, the OVA500 trial[15] were reported in 2 additional articles; 1 analyzed the performance of clinical assessment with versus without OVA1® testing[16] and the other “was undertaken to better understand the impact of ovarian imaging on the clinical interpretation of the MIA score.”[17] The sensitivity, specificity, PPV, and NPV were reported for a number of comparisons and combinations of OVA1® testing with other clinical/imaging findings. However, the authors noted that both the OVA1® and OVA500 trials were designed to measure accuracy in prediction of malignancy rather than the test’s effect on patient referral for sub-specialty care.

Grenache et al. evaluated the diagnostic performance of both the OVA1® and ROMA tests in a prospective case series of 146 women with an adnexal mass.[18] Although performance characteristics of both tests were determined and compared, the study did not evaluate diagnostic performance in conjunction with clinical assessment, as the both tests were intended to be used. OVA1® was 97% sensitive and 55% specific, and ROMA was 87% sensitive and 83% specific. This means that with clinical assessment (as intended to be used), the OVA1® test would be no worse than 97% sensitive and no better than 55% specific, but cannot be determined from the study. The same conclusions can be drawn regarding the ROMA test.

**ROMA**

Since the publication of the Wang and Dayyani meta-analysis, multiple studies have described the use of
Roma populations of women in whom decisions to pursue surgery had been made, including Al Musalhi (n=213 cases)\cite{19}, Cho et al. (n=90 cases)\cite{20}, and Terlikowska et al. (n=224 cases).\cite{21}

Diagnostic performance of the ROMA test was evaluated for FDA approval in a prospective, blinded clinical trial using 13 demographically mixed subject enrollment sites with company sponsorship.\cite{9} Patients all presented with an adnexal mass and were scheduled to undergo surgery. An Initial Cancer Risk Assessment (ICRA) was performed to determine the detection of benign versus malignant lesions before testing. The prevalence of cancer was 15%.

Using pathologic diagnosis as the gold standard, test performance, when combined with presurgical assessment for benign disease, was as follows in the hands of a mixed population of generalist and specialist physicians:

<table>
<thead>
<tr>
<th></th>
<th>ICRA alone</th>
<th>ICRA with ROMA testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>77% (66 to 86%)</td>
<td>91% (81 to 96%)</td>
</tr>
<tr>
<td>Specificity</td>
<td>84% (80 to 88%)</td>
<td>67% (61 to 71%)</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>46% (17 to 56%)</td>
<td>33% (26 to 40%)</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>96% (93 to 97%)</td>
<td>98% (95 to 99%)</td>
</tr>
</tbody>
</table>

Both tests, when added to pre-testing clinical assessment, produced a fall in the positive predictive value of diagnosis with a small increase in the negative predictive value. The changes observed in the negative predictive value were of uncertain statistical and clinical significance.

It is important to note that all of the above literature assessed ROMA as a stand-alone test and did not evaluate diagnostic performance in conjunction with clinical assessment, as the test was intended to be used. Therefore, the ability to draw conclusions regarding the test’s diagnostic performance is limited.

One study by Moore et al. did evaluate ROMA in conjunction with clinical assessment, using either positive clinical assessment or positive ROMA as a positive test (similar to the recommended usage for OVA1®).\cite{22} Using this method of combining tests guarantees a higher sensitivity and lower specificity for the combined test than for either test alone. Used in this way, ROMA would only need to be evaluated in patients with a negative clinical assessment. In this study, 461 women were enrolled, of whom a total of 86 (19%) had a malignancy. Combined assessment improved sensitivity from 77.9% to 89.7%, but worsened specificity from 84.3% to 67.2%.

No studies were identified that addressed the diagnostic performance of the Overa test.

**Conclusion**

There are a limited number of studies comparing diagnostic accuracy of the ROMA and OVA1® proteomic tests. Studies have found that ROMA has similar or lower accuracy to other risk prediction measures that use components of the standard workup, such as the RMI and the LR2 measures. Use of these tests in addition to other clinical assessment tools appears to increase sensitivity but decreases specificity. Further prospective studies are needed for both assays to understand their proper role in patient care.

**Clinical Utility**

The ideal study design to evaluate clinical utility of proteomics-based testing is a randomized controlled
trial comparing patient management decisions (e.g., referral patterns) and/or health outcomes (e.g., mortality) in patients managed with proteomic tests with those managed according to best current clinical practices.

Systematic Review

The 2012 TEC Assessment\(^{[11]}\) concluded that studies of OVA1® and ROMA showed improvements in sensitivity and worsening of specificity with the use of the tests in conjunction with clinical assessment, and that there are problems in concluding that this results in improved health outcomes. The clinical assessment performed in the studies was not well characterized. The evidence regarding the effect of OVA1® and ROMA on health outcomes is indirect, and based on studies of diagnostic performance of the tests in patients undergoing surgery for adnexal masses. The authors noted that there were no prospective studies on the use of these tests in patients who presented with an adnexal mass or studies that reported the impact of testing on referral patterns or the impact on health outcomes.

Randomized Controlled Trials

No RCTs on the effects of these tests on patient management decisions and healthcare outcomes compared with current assessment were identified.

Nonrandomized Studies

No outcome studies have been performed using the OVA1® or the ROMA test. In 2014, Kaijser et al. published a study that did not directly evaluate clinical utility but that provides relevant information.\(^{[23]}\) This retrospective cohort study included 101 newly diagnosed cases of biopsy-proven invasive ovarian cancer. Blood samples obtained before treatment were analyzed; HE4 and CA125 levels were measured and the ROMA algorithm was calculated. Median overall survival in the study cohort was 3.7 years. In a multivariate analysis controlling for confounding variables, neither HE4 levels nor ROMA were independently associated with progression-free survival (PFS) or disease-specific survival (DSS). For example, for ROMA and the outcome of PFS, the adjusted hazard ratio (HR) for each 10% increase in risk was 0.98, 95% confidence interval (CI), 0.88 to 1.11. Patients were not prospectively managed according to their HE4 levels or ROMA score and thus the actual impact of these tests on PFS and DSS cannot be determined from this study. It is not clear what impact either test would have on long-term health outcomes or referral patterns to specialty physicians. The use of proteomic testing to triage patients for malignancy may be only one of many factors in decision making about where treatment should be delivered.

Conclusion

Although current studies show improvements in sensitivity and worsening of specificity with the use of the OVA1® and ROMA tests in conjunction with clinical assessment, there are problems in concluding that this results in improved health outcomes. The clinical assessment performed in the studies is not well characterized. In addition, there is indirect evidence from studies of diagnostic accuracy which suggest that the ROMA test would not improve the accuracy of triage compared to existing measures, and is unlikely to improve the accuracy of referral to a specialist and is therefore, unlikely to improve outcomes.

Clinical Practice Guidelines and Position Statements
The Society for Gynecologic Oncology (SGO)

The SGO addresses the use of the OVA1 test in a bulletin issued in 2009.[24] This document includes the following statements:

- The OVA1 test…may be a useful tool in identifying women who should be referred to a gynecologic oncologist for their ovarian cancer surgery.
- This test has not been approved for use as an ovarian cancer screening tool, nor has it been proven to result in early detection or reduce the risk of death from this disease.
- Results from the OVA1 test should not be interpreted independently, nor be used in place of a physician’s clinical assessment.
- Physicians are strongly encouraged to reference the SGO/ACOG Pelvic Mass Guidelines to determine an appropriate care plan for their patients.

In May 2013, the Society for Gynecologic Oncology (SGO) issued the following consensus based statement on multiplex serum testing for women with pelvic masses:[25]

“Blood levels of five proteins in women with a known ovarian mass have been reported to change when ovarian cancer is present. Tests measuring these proteins may be useful in identifying women who should be referred to a gynecologic oncologist. Recent data have suggested that such tests, along with physician clinical assessment, may improve detection rates of malignancies among women with pelvic masses planning surgery. Results from such tests should not be interpreted independently, nor be used in place of a physician’s clinical assessment. Physicians are strongly encouraged to reference the American Congress of Obstetricians and Gynecologists’ 2011 Committee Opinion “The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer” to determine an appropriate care plan for their patients.”

The SGO Position Statements regarding the use of the OVA1 or ROMA test is not based upon scientific evidence and does not recommend the use of the OVA1 test as part of their referral guidelines for women who present with an adnexal mass.

The American Congress of Obstetricians and Gynecologists (ACOG)[26]

ACOG addresses the use of the serum marker testing in their practice bulletin on the Evaluation and Management of Adnexal Masses. This document states:

Serum biomarker panels may be used as an alternative to CA 125 level alone in determining the need for referral to or consultation with a gynecologic oncologist when an adnexal mass requires surgery. These biomarker panels are not recommended for use in the initial evaluation of an adnexal mass, but may be helpful in assessing which women would benefit from referral to a gynecologic oncologist. Trials that have evaluated the predictive value of these panels show potential for improved specificity, especially for evaluation of premenopausal women. However, comparative research has not yet defined the best testing approach.

The National Cancer Institute (NCI)

The NCI included a discussion of proteomics in their publication on the Genetics of Breast and Ovarian Cancer.[27] The following statement is included in their discussion on proteomics:
“These (proteomic) studies have generally been small case-control studies that are limited by sample size and the number of early-stage cancer cases included. Further evaluation is needed to determine whether any additional markers identified in this fashion have clinical utility for the early detection of ovarian cancer in the unselected clinical population of interest.” (Level of Evidence: 5; Opinions of respected authorities are based on clinical experience, descriptive studies, or reports of expert committees.)

National Comprehensive Cancer Network (NCCN)

The 2016 NCCN guidelines (v1.2016)\(^2\) include the following statement:

“It has been suggested that specific biomarkers (serum HE4 and CA125) along with an algorithm (Risk of Ovarian Malignancy Algorithm [ROMA]) may be useful for determining whether a pelvic mass is malignant or benign. The FDA has approved the use of HE4 and CA125 for estimating the risk of ovarian cancer in women with a pelvic mass. Currently, the NCCN Panel does not recommend the use of these biomarkers for determining the status of an undiagnosed pelvic mass.”

Regarding the OVA1 test, the guidelines state:

“The OVA1 test uses 5 markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) to assess who should undergo surgery by an experienced gynecologic oncologist and who can have surgery in the community. Based on data documenting an increased survival, NCCN Guidelines Panel Members recommend that all patients should undergo surgery by an experienced gynecologic oncologist (category 1).”

Summary

There is not enough research to show that multimarker serum testing to determine the risk of ovarian cancer can improve health outcomes for women with pelvic masses. Clinical guidelines based on research do not currently recommend the use of these tests for patients with pelvic masses. Therefore, all uses of these tests, including use as a screening tool for ovarian cancer, are considered investigational.

REFERENCES


7. Medical Devices: Ovarian adnexal mass assessment score test system; Labeling; Black box restrictions. 21 CFR Part 866, Federal Register 2011;76(251):82128-82123.


**CROSS REFERENCES**

*Analysis of Proteomic Patterns for Early Detection of Cancer*, Laboratory, Policy No. 41

<table>
<thead>
<tr>
<th>CODES</th>
<th>NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81500</td>
<td>Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score (This code is for reporting the ROMA™ test)</td>
</tr>
<tr>
<td></td>
<td>81503</td>
<td>Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and pre-albumin), utilizing serum, algorithm reported as a risk score (This code is for reporting the OVA1™ test)</td>
</tr>
<tr>
<td>CODES</td>
<td>NUMBER</td>
<td>DESCRIPTION</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>0003U</td>
<td>Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>